TERN-601

TERN-701, an oral BCR-ABL inhibitor for chronic myeloid leukemia, completes dose escalation phase with promising safety profile and molecular responses in heavily pre-treated patients.

The GLP-1 agonists market is projected to experience substantial growth by 2034, driven by increased awareness and efficacy in managing diabetes and obesity.

Novo Nordisk's oral amycretin demonstrated a 4% placebo-adjusted weight loss after four weeks, showing potential in glucose control and appetite regulation.

Terns Pharmaceuticals' stock is gaining traction as a potential investment opportunity in the weight loss sector, following positive Phase 1 results for its drug candidate, TERN-601.

Terns Pharmaceuticals announced positive Phase 1 results for TERN-601, an oral GLP-1R agonist, showing statistically significant weight loss of up to 5.5% over 28 days.